Skip to content

Home Electronic Monitoring of Chronic Heart Failure

Monitoring Electronique à Distance Des Patients Insuffisants Cardiaques

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02486887
Acronym
MEDIC
Enrollment
210
Registered
2015-07-01
Start date
2015-06-30
Completion date
2020-09-30
Last updated
2018-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Failure

Keywords

telemonitoring

Brief summary

The main objective of the study is to evaluate the effect of telemonitoring on mortality and rehospitalization due to heart failure on patients with chronic heart failure which have follow an educational program compared to a conventional follow-up during 1 year. The secondary objectives of the study are : * Evaluate the cost of health * Qualitatively evaluate telemonitoring on uses * Evaluate quality of life

Detailed description

prospective, monocentric, randomized open-labeled study. 1. \- Data collected 1. \- during inclusion visit sex, age, full contact details, marital status, number of child, level of education, professional status weight, height, BMI, cardiac pulse, blood pressure, NYHA, consumption of tobacco and alcohol, concomitant treatments, medical history BNP, prealbumin Quality of life questionnaire (Minnesota), Depression questionnaire (HAD), autonomy questionnaire (IADL) 2. \- at 6 month weight, height, BMI, cardiac pulse, blood pressure, NYHA, consumption of tobacco and alcohol, concomitant treatments, medical history BNP, prealbumin Number of consultations, nurses care, number of hospitalization in emergency care unit, number of hospitalization due to acute heart failure, number of days of hospitalization, number of medical transports Quality of life questionnaire (Minnesota), Depression questionnaire (HAD), autonomy questionnaire (IADL) 3. \- at one year weight, height, BMI, cardiac pulse, blood pressure, NYHA, consumption of tobacco and alcohol, concomitant treatments, medical history BNP, prealbumin Number of consultations, nurses care, number of hospitalization in emergency care unit, number of hospitalization due to acute heart failure, number of days of hospitalization, number of medical transports Quality of life questionnaire (Minnesota), Depression questionnaire (HAD), autonomy questionnaire (IADL) 2. \- Medico-economic evaluation The objective of this evaluation is to analyzed the efficiency of telemonitoring in patients with chronic heart failure. This evaluation has to be : * quantitative : directs modifications of cost and nature of health care follow-up or organization * qualitative : indirect impact on health care costs of situations or behavior 3. \- study of uses uses is faculty of recognition, comprehension, use, appropriation and diversion of the telemonitoring by patients. During the first phase, interviews to obtain qualitative vision of interactions between telemonitoring and ecosystems of players. 40 qualitative interviews during 2 hours of : 30 patients ; 24 users of telemonitoring and 6 non-users. 10 members of medical and paramedical staff The objectives of the second phase is to defined usage scenarios from previous assessments. 4.- Telemonitoring surveillance of weight, blood pressure and cardiac pulse, 3 times a week by the patient at home. H2AD platform, general practitioner, cardiology unit, therapeutical education team had to manage alarms. The devices (balance, blood pressure and pulse monitor) are related by GPRS to a medical platform. The platform receive every measure of weight, blood pressure and pulse. When weight, blood pressure or pulse increased or decreased, alarms are emitted and patients are contacted by a practitioner.

Interventions

DEVICEtelemonitoring of weight, pulse and blood pressure

Sponsors

AG2R La Mondiale
CollaboratorOTHER
IMRI
CollaboratorUNKNOWN
AFPEC
CollaboratorUNKNOWN
H2AD
CollaboratorOTHER
Pôle des Microtechniques de Besançon
CollaboratorUNKNOWN
Centre Hospitalier Universitaire de Besancon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with chronic heart failure, NYHA II, III or IV * Patients with follow-up in therapeutic education program and who had finish the program in 2011, 2012, 2013, 2014, 2015, 2016, 2017 * Information given and informed consent given

Exclusion criteria

* vital emergencies * Refusal of patient, cardiologist or general practitioner * Person who is not able to communicate or answer the questions * Patients with problems of understanding as such dure to those diseases : dementia, Alzheimer disease, or neurological sequelae of cerebral stroke * Patients who do not speak french * Patients under guardianship * Patients with other diseases which alter quality of life * Patients who participate to another clinical trial * Person private of liberty by court decision

Design outcomes

Primary

MeasureTime frame
Number of rehospitalizations due to acute heart failure and number of death due to heart failure1 year

Secondary

MeasureTime frame
Number and cost of consultations, treatments, hospitalization, transport, care of nurses ...1 year
Qualitative interviews of patients and to all medical care services about uses and services rendered by the new device1 year
Interviews of patients and comptability of alarms of non-observance of weight, pulse and arterial pressure measure to evaluate acceptability and observance of telemonitoring device1 year
Scores on questionnaires of minnesota, EQ-5D and IADL to evaluate quality of life and autonomy1 year
Mean duration of stay during hospitalization1 year
Number of hospitalization in emergency care unit to measure efficacy of telemonitoring1 year
Number of alarm for increase of weight, hypo- or hypertension, bradycardia or tachycardia as a measure of efficacy of telemonitoring1 year

Countries

France

Contacts

Primary ContactSeronde Marie-France, PH
mfseronde@chu-besancon.fr0033381668185
Backup ContactSall Fatimata, SC
fatimata.sarr@chu-besancon.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026